Cargando…

Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma

Immunomodulatory drugs (IMiDs) thalidomide, lenalidomide (Len) and pomalidomide trigger anti-tumor activities in multiple myeloma (MM) by targetting cereblon and thereby impacting IZF1/3, c-Myc and IRF4. Histone deacetylase inhibitors (HDACi) also downregulate c-Myc. We therefore determined whether...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hideshima, T, Cottini, F, Ohguchi, H, Jakubikova, J, Gorgun, G, Mimura, N, Tai, Y-T, Munshi, N C, Richardson, P G, Anderson, K C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4476017/ https://www.ncbi.nlm.nih.gov/pubmed/25978432 http://dx.doi.org/10.1038/bcj.2015.38

Ejemplares similares

Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells
por: Suzuki, Rikio, et al.
Publicado: (2015)

Antitumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma
por: Suzuki, Rikio, et al.
Publicado: (2014)

The biological significance of histone modifiers in multiple myeloma: clinical applications
por: Ohguchi, Hiroto, et al.
Publicado: (2018)

Small Molecule Multi-Targeted Kinase Inhibitor RGB-286638 Triggers P53-Dependent and -Independent Anti-Multiple Myeloma Activity through Inhibition of Transcriptional CDKs
por: Cirstea, Diana, et al.
Publicado: (2013)

Author Correction: The biological significance of histone modifiers in multiple myeloma: clinical applications
por: Ohguchi, Hiroto, et al.
Publicado: (2021)

The KDM3A–KLF2–IRF4 axis maintains myeloma cell survival
por: Ohguchi, Hiroto, et al.
Publicado: (2016)

Histone deacetylase inhibitors in multiple myeloma
por: Deleu, Sarah, et al.
Publicado: (2009)

Lenalidomide for the treatment of relapsed and refractory multiple myeloma
por: van de Donk, Niels WCJ, et al.
Publicado: (2012)

KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survival
por: Ohguchi, Hiroto, et al.
Publicado: (2017)

Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics
por: Chhabra, Saurabh
Publicado: (2017)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Clinical use and applications of histone deacetylase inhibitors in multiple myeloma
por: Tandon, Nidhi, et al.
Publicado: (2016)

Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors
por: Moreaux, J, et al.
Publicado: (2013)

Heterogeneity of B cell lymphopoiesis in patients with premalignant and active myeloma
por: Jakubikova, Jana, et al.
Publicado: (2023)

HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications
por: Harada, Takeshi, et al.
Publicado: (2017)

Histone Deacetylases and Their Inhibitors in Cancer Epigenetics
por: Hassell, Kelly N.
Publicado: (2019)

PRMT5 inhibitors on the (myeloma) road
por: Gulla, Annamaria, et al.
Publicado: (2018)

A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications
por: Jakubikova, Jana, et al.
Publicado: (2016)

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma
por: Hideshima, Teru, et al.
Publicado: (2008)

Regulation of Immune Responses by Histone Deacetylase Inhibitors
por: Licciardi, Paul V., et al.
Publicado: (2012)

Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma
por: Ramakrishnan, Vijay G., et al.
Publicado: (2019)

Targeting phosphoinositide 3-kinases and histone deacetylases in multiple myeloma
por: Okabe, Seiichi, et al.
Publicado: (2021)

Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling
por: Ho, Matthew, et al.
Publicado: (2019)

Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy
por: Richardson, Paul, et al.
Publicado: (2010)

The Effect of Vicinal Difluorination on the Conformation and Potency of Histone Deacetylase Inhibitors
por: Ariawan, A. Daryl, et al.
Publicado: (2021)

Histone deacetylase inhibitors in Hodgkin lymphoma
por: Buglio, Daniela, et al.
Publicado: (2010)

Clinical Toxicities of Histone Deacetylase Inhibitors
por: Subramanian, Srividya, et al.
Publicado: (2010)

Acetylation and Histone Deacetylase Inhibitors in Cancer
por: Kortenhorst, Madeleine S. Q., et al.
Publicado: (2006)

Histone Deacetylase Inhibitors as Anticancer Drugs
por: Eckschlager, Tomas, et al.
Publicado: (2017)

The application of histone deacetylases inhibitors in glioblastoma
por: Chen, Rui, et al.
Publicado: (2020)

Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma
por: Bae, Jooeun, et al.
Publicado: (2021)

Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
por: Yan, Wensheng, et al.
Publicado: (2012)

Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors
por: Lapierre, Marion, et al.
Publicado: (2016)

Reversing resistance to antiandrogens with a histone deacetylase inhibitor
por: Ferrari, Anna C.
Publicado: (2018)

The Treatment of Multiple Myeloma Patients Not Eligible for Asct
por: Richardson, Paul, et al.
Publicado: (2010)

Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease
por: He, Jingsong, et al.
Publicado: (2018)

Chidamide, a subtype-selective histone deacetylase inhibitor, enhances Bortezomib effects in multiple myeloma therapy
por: He, Yanjuan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ipoire2dle538ic84rj73140ju